Next Article in Journal
Cetuximab in Locally Advanced Head-And-Neck Cancer: Defining the Population
Previous Article in Journal
Sunitinib Malate for Gastrointestinal Stromal Tumour in Imatinib Mesylate–Resistant Patients: Recommendations and Evidence
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 17
Issue 4
10.3747/co.v17i4.562
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Incidence of Taxane-Induced Pain and Distress in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Retrospective, Outcomes-Based Survey

by
S. Saibil
1,
B. Fitzgerald
2,
O.C. Freedman
3,
E. Amir
1,
J. Napolskikh
1,
N. Salvo
1,
G. Dranitsaris
4 and
M. Clemons
5,*
1
Division of Medical Oncology/Haematology, Princess Margaret Hospital, Toronto, ON, Canada
2
Department of Nursing, Princess Margaret Hospital, Toronto, ON, Canada
3
Division of Medical Oncology, Durham Regional Cancer Centre, Oshawa, ON, Canada
4
Consultant in Health Economics and Biostatistics, Toronto, ON, Canada
5
Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2010, 17(4), 42-47; https://doi.org/10.3747/co.v17i4.562
Submission received: 9 May 2010 / Revised: 5 June 2010 / Accepted: 2 July 2010 / Published: 1 August 2010

Abstract

Introduction: With the widespread use of sequential anthracycline/taxane–based chemotherapy for early-stage breast cancer, clinicians are becoming rapidly aware of toxicities associated with those regimens. Despite the low incidence reported in the literature of significant arthralgia and myalgia with those regimens, it is clinically evident that a substantial proportion of patients develop such toxicities. We performed a pilot study to investigate the extent of this problem. Patients and Methods: Patients who had received prior adjuvant or neoadjuvant chemotherapy [doxorubicin–cyclophosphamide followed by paclitaxel (AC-T), doxorubicin–cyclophosphamide followed by docetaxel (AC-D), or 5-fluourouracil–epirubicin–cyclophosphamide followed by docetaxel (FEC-D)] completed a retrospective outcomes-based survey. The survey utilized the Functional Assessment of Cancer Therapy–Taxane Scale, the Memorial Symptom Assessment Scale, and a modified Brief Pain Inventory. Results: Interviews were conducted with 82 patients. Interviewees had received AC-T (43%), FEC-D (43%), and AC-D (14%). Pain as a side effect of either the anthracycline or the taxane chemotherapy was reported by 87% of patients. Most of the patients (79%) indicated that their worst pain occurred during the taxane component of treatment. Compared with paclitaxel, docetaxel was reported to cause more pain. Narcotics for pain management were required by 35 of 82 patients (43%). Conclusions: A significant number of patients receiving sequential anthracycline/taxane–based chemotherapy for early-stage breast cancer experience pain, particularly during the taxane component. Prospective patient-reported outcome assessments are needed to help individualize treatment interventions and to improve symptom management in this population.
Keywords: breast cancer; taxanes; anthracyclines; toxicities breast cancer; taxanes; anthracyclines; toxicities

Share and Cite

MDPI and ACS Style

Saibil, S.; Fitzgerald, B.; Freedman, O.C.; Amir, E.; Napolskikh, J.; Salvo, N.; Dranitsaris, G.; Clemons, M. Incidence of Taxane-Induced Pain and Distress in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Retrospective, Outcomes-Based Survey. Curr. Oncol. 2010, 17, 42-47. https://doi.org/10.3747/co.v17i4.562

AMA Style

Saibil S, Fitzgerald B, Freedman OC, Amir E, Napolskikh J, Salvo N, Dranitsaris G, Clemons M. Incidence of Taxane-Induced Pain and Distress in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Retrospective, Outcomes-Based Survey. Current Oncology. 2010; 17(4):42-47. https://doi.org/10.3747/co.v17i4.562

Chicago/Turabian Style

Saibil, S., B. Fitzgerald, O.C. Freedman, E. Amir, J. Napolskikh, N. Salvo, G. Dranitsaris, and M. Clemons. 2010. "Incidence of Taxane-Induced Pain and Distress in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Retrospective, Outcomes-Based Survey" Current Oncology 17, no. 4: 42-47. https://doi.org/10.3747/co.v17i4.562

APA Style

Saibil, S., Fitzgerald, B., Freedman, O. C., Amir, E., Napolskikh, J., Salvo, N., Dranitsaris, G., & Clemons, M. (2010). Incidence of Taxane-Induced Pain and Distress in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Retrospective, Outcomes-Based Survey. Current Oncology, 17(4), 42-47. https://doi.org/10.3747/co.v17i4.562

Article Metrics

Back to TopTop